http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102016025008-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16d0ba9db772521ff1d70197ff3f95d6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate | 2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d594eec5e33ba85953d969439fd5cc69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9dc7d59abb725379c8069eb45fb9724 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507a0e6169ddcb0b9985c47d3694b7d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fde38a5bb606133e09242b17a7f65242 |
| publicationDate | 2018-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102016025008-A2 |
| titleOfInvention | MICROPARTICULATED BIOPOLYMER SYSTEM FOR CONTROLLED METRONIDAZOLE RELEASE. |
| abstract | Metronidazole is an antiprotozoan drug widely known for its amoebic action. Oral administration of this drug has a number of adverse effects, the most common of which are nausea, diarrhea and other gastrointestinal disorders. In addition, a metallic taste is produced in the mouth during treatment. The present invention relates to the development of a microparticulate biopolymeric system based on the polyelectrolytic polymeric complex (cpe) formed from the ionic interaction between chitosan and carboxymethylcellulose (chi-cmc). the microparticle (chi-cmc) formed in water / oil emulsion has high porosity. the drug-containing microparticulate bi-polymeric biopolymeric system is a differentiated metronidazole drug transport system, maintaining effective drug concentration (dose-effect or plasma-dose) for a prolonged time in the human body. added value by controlled release and decreased toxicity of the drug in the body. allowing controlled release at both ph 1.2, ph from the stomach, and ph 6.8, ph from the intestine, making it the ideal system for patients with stomach and intestinal disorders who usually could not use a drug to metabolize at this site. |
| priorityDate | 2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.